within Pharmacolibrary.Drugs.ATC.J;

model J01MA17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.45,
    Cl             = 0.000135,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.086,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.025666666666666667,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01MA17</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Prulifloxacin is a synthetic broad-spectrum fluoroquinolone antibacterial agent, used primarily for the treatment of urinary tract infections and respiratory tract infections. It is a prodrug, rapidly metabolized to the active compound ulifloxacin. Prulifloxacin is approved for use in some countries, mainly in Europe and Asia, but is not available in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Picollo, R, et al., &amp; Dionisio, P (2003). Pharmacokinetics and tolerability of prulifloxacin after single oral administration. <i>Arzneimittel-Forschung</i> 53(3) 201–205. DOI:<a href=&quot;https://doi.org/10.1055/s-0031-1297095&quot;>10.1055/s-0031-1297095</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12705176/&quot;>https://pubmed.ncbi.nlm.nih.gov/12705176</a></p></li><li><p>Haque, E, &amp; Georg, GI (2025). Medoxomil Prodrug Strategies. <i>Journal of medicinal chemistry</i> 68(9) 9025–9036. DOI:<a href=&quot;https://doi.org/10.1021/acs.jmedchem.4c02967&quot;>10.1021/acs.jmedchem.4c02967</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40261681/&quot;>https://pubmed.ncbi.nlm.nih.gov/40261681</a></p></li><li><p>Giannarini, G, et al., &amp; Selli, C (2009). Prulifloxacin: clinical studies of a broad-spectrum quinolone agent. <i>Future microbiology</i> 4(1) 13–24. DOI:<a href=&quot;https://doi.org/10.2217/17460913.4.1.13&quot;>10.2217/17460913.4.1.13</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19207096/&quot;>https://pubmed.ncbi.nlm.nih.gov/19207096</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01MA17;
